Sequent Scientific Sets December 8 As Record Date for Viyash Shareholders Ahead of Merger Share Allotment

Mumbai, November 27, 2025: Sequent Scientific Limited has announced December 8, 2025, as the record date to allocate merger consideration shares to shareholders of Viyash Life Sciences Private Limited. The date will determine which Viyash shareholders are eligible to receive Sequent equity under the Board-approved Merger Plan. Only those holding Viyash shares as of the record date will be entitled to the allotted Sequent shares, marking a key step in the company’s ongoing multi-entity amalgamation strategy.

Share Exchange Ratio Finalized

This merger has defined an exchange rate which will see Sequent making payment to Viyash Life Sciences shareholders of 56 total free shares for every 100 total fully paid free shares of Viyash Life Sciences. The share exchange is just one part of a much larger multi-company merger, along with many other companies, including Symed Labs, Vindhya Organics, Appcure Lands, and others. The specific exchange rate is established to allow sufficient and equitable distribution of Sequent due to Viyash’s eventual inclusion in this collective group of companies.

Before and After Snapshot

Shareholders eligible for the merger consideration will be determined based on the record date of December 8, 2025. Only those holding Viyash shares as of this date will receive Sequent equity. Under the approved exchange ratio, 56 Sequent shares will be issued for every 100 Viyash shares held, giving investors a clear understanding of their ownership stake after the merger.

Share Exchange Details

The share exchange agreement outlines the stock values, with each Sequent share having a face value of ₹2 and each Viyash share a face value of ₹10. Despite the difference in face values, the exchange ratio remains 56 Sequent shares for every 100 Viyash shares, providing a clear framework for how shareholders’ holdings will convert post-merger.

Company Confirmation

The record date has been set following the certification of the NCLT order approving the composite scheme, as previously communicated by the Company. Sequent Scientific aims to ensure the accurate identification of all eligible shareholders and facilitate the timely issuance of merger consideration shares.

Share Market Snapshot

As of 11:15 AM, the share price of Sequent Scientific Limited was trading at ₹226.57, up 3.32% from its previous close of ₹219.28. The share opened at ₹221.44 and traded between ₹235.60 and ₹221.44, high and low so far.

Sequent Scientific Limited, an integrated pharmaceutical company specialising in animal health APIs and formulations, is listed on both the NSE and BSE. The company has consistently expanded through strategic acquisitions, mergers, and other growth initiatives, strengthening its operations across the life sciences sector. The upcoming share allotment marks a significant milestone in Sequent’s journey toward a more consolidated and streamlined life sciences business.

REF: https://nsearchives.nseindia.com/corporate/SEQUENT1_26112025182610_Record_date_2_Disclosure.pdf

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations